This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s Lev Gerlovin and co-authors Walter Colasante and Pascale Diesel published a series of three articles in Cell & Gene on emerging gene and cell therapies and their impact on the market.
Read the full series below:
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
Investing in the prevention and treatment of non-communicable diseases (NCDs) can strengthen health systems, protect economic productivity, and improve...
